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Lung adenocarcinoma cells harboring oncogenic rearrangements of the gene encoding anaplastic lymphoma kinase (ALK), such as EML4-ALK, are typically dependent upon the oncogene for survival. Hence, treatment with an ALK tyrosine-kinase inhibitor (crizotinib or ceritinib) often elicits profound initial anti-tumor responses in ALK fusion-positive (ALK + ) patients with lung adenocarcinoma 1-3 . However, complete, durable responses to ALK-inhibitor monotherapy are rare, and patients invariably succumb to the emergence of drugresistant disease (acquired resistance). Furthermore, up to 40% of ALK + patients fail to respond initially to ALK-inhibitor therapy and exhibit innate resistance 2,4 . Identifying molecular events that limit the response to ALK inhibition is essential for enhancing clinical outcomes.
In most oncogene-driven cancers, including ALK + lung cancers, efforts to combat resistance have focused on treating acquired resistance after it has emerged 2 . One alternative strategy for enhancing the initial response and suppressing acquired resistance is to deploy rational upfront polytherapies that target the primary oncoprotein (such as EML4-ALK) and a critical effector of that oncoprotein 5, 6 . This strategy has been successful in patients with BRAF V600E -mutant melanoma, in whom upfront (but not second-line) inhibition of the primary driver BRAF V600E plus its primary effector, MEK1/2, exhibits activity superior to that of RAF-or MEK-inhibitor monotherapy 5, [7] [8] [9] .
The optimal upfront co-targeting strategy is less clear in tumors harboring an oncoprotein that engages multiple effector pathways, such as receptor tyrosine kinases (RTKs) 10 . Mutant EGFR and ALK, ROS1 or RET gene rearrangements are prominent oncogenic RTKs in lung adenocarcinoma 11 . A rational co-targeting strategy requires understanding of the signaling events that are most critical for survival in tumor cells with a particular oncogenic RTK. We addressed this knowledge gap in EML4-ALK lung adenocarcinoma to provide insight into the oncogenic function of ALK and identify a rational upfront polytherapy strategy to enhance patient survival.
RESULTS

EML4-ALK lung adenocarcinoma cells depend on MAPK
EML4-ALK signals via the PI3K-AKT, MAPK and JAK-STAT pathways 3 (Fig. 1a) . Which effector is most critical for EML4-ALKdriven cell survival is unclear. We investigated downstream pathway dependencies in EML4-ALK lung adenocarcinoma cells, focusing on the most common ALK fusion variant in lung adenocarcinoma (EML4-ALK E13:A20, variant 1) 11 . The ALK inhibitors crizotinib or ceritinib decreased cell growth and the abundance of phosphorylated (p-) ALK, p-ERK, p-AKT and p-STAT3 in two patient-derived EML4-ALK (E13:A20) cell lines, H3122 and STE-1 (ref. 12) (Fig. 1b) . Inhibition of MAPK (via MEK inhibition), but not of PI3K-AKT or JAK-STAT, suppressed cell growth similar to inhibition of ALK ( Fig. 1c and Supplementary Fig. 1a-d) . Conversely, constitutive genetic activation of MAPK signaling at the level of the GTPase RAS (KRAS G12V/C/D ), RAF (BRAF V600E ) or (MAP2K1 S218D,S222D , MEK DD ) 13 rescued EML4-ALK lung adenocarcinoma cells from ALK inhibition, whereas genetic activation of AKT signaling (via myristoylated AKT) did not (Fig. 1d-g and Supplementary Figs. 1e-g and 2a-g ). K-RAS G12V -expressing cells rescued MAPK signaling, but not AKT signaling, in the presence of ALK inhibition (Fig. 1e) . Genetic activation of STAT3 partially rescued EML4-ALK lung adenocarcinoma cells from the effects of treatment with an ALK inhibitor, consistent with published work 14 , although modestly so compared with the activation of MAPK ( Supplementary Fig. 2a-h ). These data reveal a specific and primary requirement for MAPK signaling in EML4-ALK lung adenocarcinoma cells.
We explored whether the MAPK dependence noted above was present generally in oncogene-driven lung cancer. Most lung adenocarcinomas harbor a genetic lesion encoding a product capable of hyperactivating MAPK signaling, including oncogenic KRAS, BRAF, EGFR, MEK, ERBB2, MET, ALK, RET and ROS1, among other events in the MAPK pathway 11 . MEK inhibitors have shown limited efficacy in lung adenocarcinoma patients to date, which indicates the need for better definition of tumor subsets that are most MEK dependent 15 . We found that the EML4-ALK models were among the most sensitive to MEK inhibition in a panel of oncogene-driven lung adenocarcinoma models (Fig. 1h,i and Supplementary Fig. 3 ). This MEK-inhibitor sensitivity in EML4-ALK models was similar to that observed in lung adenocarcinoma cells with oncogenic K-RAS or BRAF, but not to that of cells with oncogenic EGFR, which had little response to the MEK inhibitor trametinib (Fig. 1h,i and Supplementary Fig. 3 ). The data reveal the specificity of dependence on the MAPK pathway in ALK + lung adenocarcinoma cells.
EML4-ALK cells activate RAS-MAPK via the EML4 HELP domain
Although GTPases of the RAS family canonically link RTKs to MAPK signaling, whether oncogenic ALK fusion proteins activate RAS to promote MAPK signaling is unknown. Using GST-RAS-binding domain (RBD) affinity capture 16 , we found that activation of RAS was coupled to ALK signaling in both H3122 cells and STE-1 cells (Fig. 2a,b) . As three major RAS isoforms (H-RAS, N-RAS and K-RAS) typically function in cancer cells, we explored which isoform(s) was (were) coupled to EML4-ALK in lung adenocarcinoma cells. Using RAS isoform-specific antibodies 17 , we found that all three RAS isoforms were activated by EML4-ALK in lung adenocarcinoma cells (Fig. 2a,b) . Although genetic silencing of each RAS isoform individually had no effect on signaling or cell viability, simultaneous knockdown of all three substantially suppressed cell growth and the abundance of p-ERK but not that of p-STAT3 or p-AKT (Fig. 2c,d and Supplementary Fig. 4a ). These results suggest that RAS controls MAPK signaling, but not STAT3 or AKT signaling, downstream of EML4-ALK in lung adenocarcinoma cells.
We investigated how EML4-ALK might engage RAS. Signaling via RAS to its downstream effector pathways typically occurs on a cellular membrane compartment (either the plasma membrane or intracellular membranes) 16, 18, 19 . All ALK fusions reported in lung adenocarcinoma contain the kinase domain of ALK but not the native ALK transmembrane domain that enables membrane anchoring 20, 21 . We first examined the subcellular distribution of EML4-ALK using immunofluorescence staining of endogenous ALK in H3122 and STE-1 lung adenocarcinoma cell lines. Endogenous EML4-ALK resided on an intracellular compartment but not the plasma membrane, where many native receptor kinases engage RAS (Fig. 2e) . We investigated how a fusion protein with no known membrane-anchoring domain might engage effectors that require a lipid interface to signal, such as RAS, potentially from an intracellular locale. The EML4 portion of EML4-ALKv1 contains Basic, HELP and WD-repeat domains (Fig. 2f) . The HELP domain of EML4 consists of approximately 50% hydrophobic residues, which suggests that it might mediate membrane association and access to effectors such as RAS. Although the function of the EML4 HELP domain is poorly understood, removal of it impairs the transforming capacity of EML4-ALK 22 , and it can regulate EML4's subcellular localization 23, 24 . We hypothesized that the HELP domain in the EML4 component of the EML4-ALK fusion might be required for proper EML4-ALK localization and RAS-MAPK signaling. We introduced wild-type EML4-ALK (EML4-ALK WT ) or a mutant form lacking the HELP domain (∆HELP) into non-transformed lung epithelial (Beas2B) cells and examined EML4-ALK localization and signaling. Overexpressed EML4-ALK WT was present on a distinct intracellular compartment, as assessed by immunofluorescence staining, similar to endogenous EML4-ALK (Fig. 2g) . In contrast, the ∆HELP EML4-ALK mutant did not display this discrete intracellular localization but instead exhibited diffuse cytoplasmic expression (Fig. 2g) . Furthermore, expression of EML4-ALK WT activated ERK and also STAT3, but not AKT, in both Beas2B cells and 293T cells (Fig. 2h) . Moreover, expression of EML4-ALK WT enhanced the GTP loading of each RAS isoform (Fig. 2i) . Deletion of the HELP domain impaired the ability of EML4-ALK to activate ERK and RAS in both Beas2B cells and 293T cells (Fig. 2h,i) . Moreover, activation of EML4-ALK was uncoupled from RAS activation and MAPK signaling in H2228 lung adenocarcinoma cells that endogenously expressed a rarer EML4-ALK variant (3b) in which EML4 lacks the HELP domain 25 ( Supplementary Fig. 4b ). In these H2228 cells, inhibition of ALK failed to suppress RAS-GTP, p-ERK or cell viability ( Supplementary  Fig. 4c-f ). H2228 cells were less sensitive to MEK inhibition than were H3122 or STE-1 cells ( Supplementary Figs. 3 and 4g) . Thus, the HELP domain of EML4 in EML4-ALK might regulate EML4-ALK's subcellular localization and be critical for the activation of RAS-MAPK by EML4-ALK.
Superiority of upfront ALK + MEK polytherapy
Our data indicated that inhibition of ALK was insufficient to fully abrogate MAPK signaling in EML4-ALK lung adenocarcinoma cells (Fig. 1b,e,f) . We hypothesized that elimination of this residual MAPK signaling by treatment with sub-maximal doses of MEK inhibitor combined with an ALK inhibitor might enhance the response. The use of a sub-maximal dose of MEK inhibitor is an attractive option, given the clinical toxicity of MEK-inhibitor monotherapy at maximally tolerated doses 26, 27 . The addition of a low dose of trametinib (1 nM) sensitized H3122 and STE-1 cells to inhibition of ALK, with concurrent treatment with trametinib and crizotinib eliciting greater apoptosis than either monotherapy ( Fig. 3a-d and Supplementary  Fig. 5d ). Treatment with the distinct MEK inhibitor selumetinib or with the ERK inhibitor SCH772984 also suppressed cell growth and enhanced the response to the ALK inhibitor alectinib in H3122 cells Fig. 5a ). In contrast, trametinib did not sensitize EGFR-mutant lung adenocarcinoma cells to the EGFR inhibitor erlotinib ( Supplementary Fig. 5b,c) . The superior efficacy of combined inhibition of ALK plus inhibition of the MAPK pathway we observed in vitro was confirmed in vivo with H3122 tumor xenografts, in which substantial tumor regressions occurred only upon treatment with the ALK inhibitor plus trametinib ( Fig. 3e and Supplementary Fig. 6a ).
We observed residual MAPK activity in vivo in the tumors treated with ALK-inhibitor monotherapy (ceritinib, at a dose of 25 mg per kg body weight (mg/kg)), and this residual MAPK signaling was suppressed by the addition of a sub-maximal dose of trametinib (1 mg/kg; Fig. 3f ). Whereas mice treated with the maximal tolerated dose of trametinib alone (3 mg/kg) exhibited substantial systemic toxicity, the combination of the ALK inhibitor and a sub-maximal dose of trametinib (1 mg/kg) did not cause significant toxicity ( Supplementary  Fig. 6b ). We similarly observed superior in vivo tumor responses and safety in mice harboring STE-1 xenografts treated with combined crizotinib and (sub-maximal) trametinib, compared with results obtained for each monotherapy (Fig. 3g,h and Supplementary  Fig. 6c ). Although activated STAT3 modestly decreased sensitivity to an ALK inhibitor (Supplementary Fig. 2 ), treatment with a JAK inhibitor did not affect tumor growth or response to an ALK inhibitor in EML4-ALK cell lines and tumor xenografts ( Supplementary  Fig. 6d-f) , which suggested specificity of the effects of MEK inhibition on the response to an ALK inhibitor. Our findings show the potential utility, feasibility and specificity of combined ALK inhibitor-MEK inhibitor polytherapy to enhance the initial response in EML4-ALK lung adenocarcinoma.
KRAS WT copy-number gain promotes ALK-inhibitor resistance On the basis of our findings, we hypothesized that the development of acquired resistance to an ALK inhibitor might consistently require re-activation of the RAS-MAPK pathway. We developed multiple in vitro models of acquired resistance to an ALK inhibitor by continuously exposing H3122 cells to either crizotinib ('crizotinib acquired resistance' (CAR); n = 3 sub-lines) or ceritinib ('LDK378 acquired resistance' (LAR); n = 3 sub-lines) and explored the basis of resistance in the sub-lines derived. Each resistant sub-line was cross-resistant to each ALK inhibitor ( Fig. 4a and Supplementary Fig. 7a,b) . By DNAsequencing analysis of ALK, we detected no on-target mutations or alterations in ALK copy number in these sub-lines 28 (data not shown).
As we found that each in vitro model of ALK-inhibitor resistance showed re-activation of the MAPK pathway during treatment with the ALK inhibitor (Fig. 4b) , we investigated whether MAPK signaling was required for resistance. All of the resistant models retained substantial MAPK signaling (MEK) dependence, whereas suppression of JAK-STAT or PI3K-AKT signaling had less impact ( Fig. 4c and Supplementary Fig. 7c ). Thus, MAPK signaling was rescued and was necessary for acquired resistance to the ALK inhibitor. We sought to identify the mechanisms by which the ALK inhibitorresistant models rescued MAPK signaling, focusing on the crizotinibresistant models because this ALK inhibitor is currently most (Fig. 4d, Supplementary  Fig. 8a and data not shown). CAR1 cells had substantially higher levels of KRAS4A-4B transcripts, K-RAS protein and RAS-GTP than did the parental H3122 cells (Fig. 4e and Supplementary Fig. 8b) . Knockdown of K-RAS decreased viability and the abundance of p-ERK and increased apoptosis and sensitivity to crizotinib in CAR1 cells (Fig. 4f,g and Supplementary Fig. 8c-e) . Conversely, overexpression of KRAS WT promoted resistance to crizotinib in STE-1 and H3122 cells (Fig. 4h,i and Supplementary Fig. 9a,b) . These data identify amplification of KRAS WT as a mechanism of resistance to an ALK inhibitor.
To explore the clinical relevance of the findings reported above, we obtained tumor biopsies from patients (n = 15) with acquired resistance to ALK-inhibitor therapy and analyzed the biopsies for evidence of KRAS copy-number gain (Supplementary Fig. 8f ).
We observed focal amplification of KRAS in three patients (3 of 15; 20%) with acquired resistance to the ALK inhibitor, as determined by FISH analysis of KRAS in pre-treatment and post-resistance tumor biopsies (Fig. 4j) . The pre-treatment tumor biopsy showed no evidence of KRAS amplification in each case (Fig. 4j) , which suggested that this event emerged during the onset of resistance to crizotinib. These resistant tumors with KRAS amplification had no evidence of mutations in ALK, KRAS or BRAF (Supplementary Fig. 8f) , which supported the proposal of a primary role for amplification of KRAS WT in ALK-inhibitor resistance.
In seven other resistant tumor samples (7 of 15; 47%), we discovered KRAS WT gene-duplication events in tumor-cell sub-populations ( Supplementary Figs. 8f and 9c) . Although the function of gene duplication of KRAS WT is unknown, gene duplication of BRAF WT or PTPN11 WT (the wild-type gene encoding the tyrosine phosphatase SHP-2) can drive MAPK activation and tumor growth 29, 30 . We explored the functional effect of KRAS WT gene duplication, which might produce lower levels of KRAS than genomic amplification, by assessing the relationship between low or high levels of KRAS WT expression and ALK-inhibitor sensitivity. Expression of high or low levels of KRAS WT increased the abundance of p-ERK and promoted resistance to treatment with an ALK inhibitor in H3122 cells (Supplementary Fig. 9a,b) . Thus, KRAS gene duplication might promote MAPK signaling and ALK-inhibitor resistance. Our findings npg reveal KRAS WT copy-number gain as a mechanism of ALK-inhibitor resistance in patients with lung adenocarcinoma.
DUSP6 loss promotes ALK-inhibitor resistance
We investigated the mechanism by which CAR2 and CAR3 cells rescued MAPK signaling and became resistant to the ALK inhibitor. CAR2 and CAR3 cells had lower basal levels of RAS-GTP than that of H3122 parental cells, despite having substantial basal phosphorylation of ERK ( Fig. 4b and Supplementary Fig. 10a ). This finding suggested that re-activation of the MAPK pathway might have occurred via deregulation of components acting downstream of RAS. Phosphatases of the DUSP ('dual-specificity phosphatase') family are critical regulators of MEK-ERK signaling and typically control MAPK signaling at a level below RAS 31, 32 . To determine if a specific DUSP might regulate MAPK signaling in EML4-ALK lung adenocarcinoma cells, we examined the levels of members of the DUSP family in transcriptome data sets generated from H3122 parental cells and their ALK inhibitor-resistant derivatives. DUSP6 exhibited higher expression than that of other members of the DUSP family in parental H3122 cells (Supplementary Fig. 10b ). Moreover, DUSP6 was significantly downregulated in the sub-lines CAR2 and CAR3 ( Fig. 5a and Supplementary  Fig. 10b ). We hypothesized that downregulation of DUSP6 might promote reactivation of MAPK and ALK-inhibitor resistance in EML4-ALK lung adenocarcinoma cells. Stable reconstitution of DUSP6 in CAR2 and CAR3 cells restored sensitivity to crizotinib and the ability of crizotinib to suppress MAPK signaling (Fig. 5b,c) . 
npg
Knockdown of DUSP6 also promoted resistance to crizotinib in parental H3122 cells, an effect accompanied by rescue of p-ERK during ALK inhibition (Fig. 5d-f) . Thus, loss of DUSP6 drives ALK-inhibitor resistance in EML4-ALK lung adenocarcinoma cells.
We sought to clinically validate the findings reported above using an immunohistochemistry assay to measure DUSP6 levels in tumors obtained from patients. We conducted a comparative analysis of DUSP6 expression in an additional cohort of treatment-naive and post-ALK-inhibitor-resistance tumor samples from patients (n = 25). DUSP6 was generally lower in samples obtained after they developed resistance to ALK inhibitor than in the pre-treatment tumor specimens (Fig. 5g,h and Supplementary Fig. 10c ). In five of six (80%) of the paired tumor biopsies from individual patients in this cohort, DUSP6 expression was lower in the resistant tumor than in the corresponding pre-treatment tumor (Fig. 5g,h ). Together our clinical data support the proposal of a critical role for MAPK signaling in EML4-ALK lung adenocarcinoma and identify KRAS WT copy-number gain and DUSP6 loss as mechanisms of ALK-inhibitor resistance.
Five patients with resistance to crizotinib in our cohort (#13:KRAS amp +, #14:KRAS amp+, #15:DUSP6 score 0, #18:DUSP6 score 2, #20: DUSP6 score 0) subsequently received either an investigational ALK inhibitor (ASP3026) or ceritinib, and four of the five experienced relatively rapid disease progression (within 2-4 months) ( Supplementary  Fig. 10c ). These data further support the proposal of a potentially important role for increased KRAS WT and decreased DUSP6 in limiting the ALK-inhibitor response in patients.
Upfront co-inhibition of ALK-MEK enhances responses
The activation of MAPK can occur via a diverse set of mechanisms in ALK + lung adenocarcinoma cells, including KRAS WT amplification and DUSP6 downregulation or RTK signaling 12, 28, [33] [34] [35] , or KRAS mutations or loss of NF1 (which encodes a neurofibromatosis protein) (more generally) 36 . We hypothesized that blocking MAPK signaling upfront would minimize the emergence of resistance in ALK-inhibitor-naive lung adenocarcinoma cells. Treatment with a sub-maximal dose of trametinib (1 nM) plus crizotinib suppressed the development of acquired resistance, and the use of a modestly higher dose of trametinib (10 nM) prevented resistance altogether in both H3122 cells and STE-1 cells in vitro (Fig. 6a,b) . Moreover, polytherapy with ceritinib and a sub-maximal dose of trametinib enhanced the magnitude of the initial response and forestalled the development of acquired resistance to ceritinib monotherapy in vivo in the H3122 tumor model (Fig. 6c) . Our data provide a rationale for upfront ALK-inhibitor-MEK inhibitor polytherapy to enhance the initial response and eliminate the onset of acquired resistance in ALK + lung adenocarcinoma.
DISCUSSION
We have established the RAS-MAPK signaling axis as the primary EML4-ALK effector pathway required for the survival of EML4-ALK lung adenocarcinoma cells (Fig. 6d, left panel) . EML4-ALK activates all three major RAS isoforms, which leads to substantial RAS-MAPK signaling output that probably explains the specific MAPK dependence of EML4-ALK lung adenocarcinoma models. This RAS-MAPK dependence represents a therapeutic opportunity, as sub-maximal treatment with a MEK inhibitor can enhance the initial anti-tumor effects of ALK-inhibitor therapy by dampening RAS-MAPK output (Fig. 6d, middle panels) . This synergistic upfront dual ALK inhibitor-MEK inhibitor polytherapy can also lead to a more durable response by minimizing the opportunity for tumor cells to survive and evolve to develop resistance during initial therapy, thus forestalling acquired resistance (Fig. 6d, middle and right panels) .
Our findings highlight reactivation of MAPK signaling as a hallmark feature of acquired ALK-inhibitor resistance in lung adenocarcinoma cells. The mechanisms of resistance to ALKinhibitor treatment we have reported here and those described previously 12, 28, [33] [34] [35] [36] [37] [38] [39] can all activate MAPK signaling. Hence, MAPKpathway re-activation (via diverse mechanisms) might be a necessary event for the development of ALK-inhibitor resistance. Published work has suggested that inhibition of MEK might be effective in treating ALK-inhibitor resistance after it has occurred (as second-line therapy) 35, 40 . Our study has identified the innate dependence of EML4-ALK lung adenocarcinoma on RAS-MAPK signaling and its underlying mechanistic basis and offers an alternative approach for the treatment of patients with ALK + lung adenocarcinoma. The upfront ALK inhibitor-MEK inhibitor polytherapy strategy supported by our findings might convert the incomplete and temporary responses obtained with crizotinib, as well as those obtained with more potent ALK inhibitors such as ceritinib and alectinib, into complete, sustained remissions in patients.
METHODS
Methods and any associated references are available in the online version of the paper. 
